Colloidal drug delivery systems in vaccine delivery

Current Drug Targets

Volumn 14, Issue 1, 2013, Pages 123-137

  Beg, Sarwar ^a   Samad, Abdus ^b   Nazish, Iram ^a   Sultana, Ruksar ^c   Rahman, Mahfoozur ^d   Ahmad, Md Zaki ^d   Akbar, Md ^a  

^a HAMDARD UNIVERSITY   (India)

^b Sunflag Hospital   (India)

^c NATIONAL INSTITUTE OF TECHNOLOGY   (India)

^d Dreamz College of Pharmacy   (India)

Author keywords

Carbon nanotubes; Immune Adjuvants; Immunization; Nanocarriers; Vesicular carriers

Indexed keywords

BACTERIAL VACCINE; CARBON NANOTUBE; DENDRIMER; DIPHTHERIA VACCINE; E.COLI VACCINE; EMEPEPIMUT S; HEPATITIS A VACCINE; INFLUENZA VACCINE; LIPOSOME; LIPOVAXIN; MENINGOCOCCUS VACCINE; MICROSPHERE; NASALFLU; NIOSOME; PNEUMOCOCCUS VACCINE; PROTEASOME; PROTOLLIN; RECOMBINANT HEPATITIS B VACCINE; SHIGELLA FLEXNERI 2A VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; VACCINE; VIROSOME; WART VIRUS VACCINE;

DIPHTHERIA; DRUG DELIVERY SYSTEM; ENCAPSULATION; ESCHERICHIA COLI INFECTION; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA; LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE TRANSITION; POLYMERIZATION; REVIEW; SHIGELLOSIS; TETANUS; VIRUS LIKE AGENT; ZETA POTENTIAL;

EID: 84876743815     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945013804806523     Document Type: Review

References (157)

1. Moingeon P, Taisne Cd, Almond J. Delivery technologies for human vaccines. Br Med Bull 2002; 62: 29-44.
2. Gupta PN, Vyas SP. Colloidal carrier systems for transcutaneous immunization. Curr Drug Targets 2011; 12(4): 579-97.
3. Shahiwala A, Vyas TK, Amiji MM. Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat Drug Deliv Formul 2007; 1(1): 1-9.
4. Gregoriadis G, Allison AC. Entrapment of proteins in liposomes prevents allergic reactions in pre-immunised mice. FEBS Lett 1974; 45(1): 71-4.
5. Alving CR. Liposomes as carriers of antigens and adjuvants. J Immunol Methods. 1991 Jun 24; 140(1): 1-13.
6. Alving CR, Rao M. Lipid A and liposomes containing lipid A as antigens and adjuvants. Vaccine 2008; 26(24): 3036-45.
7. Griebel PJ, Hein WR. Expanding the role of Peyer's patches in Bcell ontogeny. Immunol Today 1996; 17(1): 30-9.
8. Mozafari MR. Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett 2005; 10(4): 711-9.
9. Frederiksen L, Anton K, van Hoogevest P, et al. Preparation of liposomes encapsulating water-soluble compounds using supercritical carbon dioxide. J Pharm Sci 1997; 86(8): 921-8.
10. Zolnik BS, Gonzalez-Fernandez A, Sadrieh N, et al. Nanoparticles and the Immune System. Endocrinol 2010; 151: 458-6.
11. Mozafari MR. Bioactive entrapment and targeting using nanocarrier technologies: an introduction. In: Nanocarrier technologies: frontiers of nanotherapy; Mozafari MR, Ed. Dordrecht, The Netherlands: Springer; 2006.
12. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001; 106(3): 255-8.
13. Nakanishi T, Kunisawa J, Hayashi A, et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. J Control Release 1999; 61(1-2): 233-40.
14. Copland MJ, Baird MA, Rades T, et al. Liposomal delivery of antigen to human dendritic cells. Vaccine 2003; 21(9-10): 883-90.
15. Reddy R, Zhou F, Huang L, et al. pH sensitive liposomes provide an efficient means of sensitizing target cells to class I restricted CTL recognition of a soluble protein. J Immunol Methods 1991; 141(2): 157-63.
16. van Rooijen N, van Nieuwmegen R. Liposomes in immunology: evidence that their adjuvant effect results from surface exposition of the antigens. Cell Immunol 1980; 49(2): 402-7.
17. Raphael L, Tom BH. Liposome facilitated xenogeneic approach for studying human colon cancer immunity: carrier and adjuvant effect of liposomes. Clin Exp Immunol 1984; 55(1): 1-13.
18. Gregoriadis G, Davis D, Davies A. Liposomes as immunological adjuvants: antigen incorporation studies. Vaccine 1987; 5(2): 145-51.
19. Hedlund G, Jansson B, Brodin T, et al. In vivo use of liposomeincorporated membrane antigens. In: Liposomes as drug carriers, Gregoriadis G, Ed. New York: John Wiley and Sons; 1988. p. 167-82.
20. Alpar HO, Eyles JE, Williamson ED, Somavarapu S. Intranasal vaccination against plague, tetanus and diphtheria. Adv Drug Deliv Rev 2001; 51(1-3): 173-201.
21. Martin C, Somavarapu S, Alpar HO. Mucosal delivery of diphtheria toxoid using polymer-coatedbioadhesive liposomes as vaccine carriers. J Drug Del Sci Tech 2005; 15(4): 301-6.
22. Henriksen-Lacey M, Korsholm KS, Andersen P, et al. Liposomal vaccine delivery systems. Expert Opin Drug Deliv 2011; 8(4): 505-19.
23. Rescia VC, Takata CS, de Araujo PS, et al. Dressing liposomal particles with chitosan and poly(vinylic alcohol) for oral vaccine delivery. J Mar Res 2011; 21(1): 38-45.
24. Tafaghodi M, Jaafari MR, Sajadi Tabassi SA. Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN. Eur J Pharm Biopharm 2006; 64(2): 138-45.
25. Christensen D, Korsholm KS, Andersen P, et al. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 2011; 10(4): 513-21.
26. Christensen D, Agger EM, Andreasen LV, et al. Liposome-based cationic adjuvant formulations (CAF): past, present, and future. J Liposome Res 2009; 19(1): 2-11.
27. Saupe A, McBurney W, Rades T, et al. Immunostimulatory colloidal delivery systems for cancer vaccines. Expert Opin Drug Deliv 2006; 3(3): 345-54.
28. Vector of membrane fusogenic liposomes used for melanoma vaccine. Cancer Vaccine. [Online] http://www.highbeam.com/doc/1G1-118046656.html (Accessed on June 11th 2012).
29. Lipovaxin. [Online] http://www.lipotek.com.au/technology/lipovaxin.htm (Accessed on 26th May 2010).
30. Yoshioka T, Skalko N, Gursel M, et al. A non-ionic surfactant vesicle-in-water-in-oil (v/w/o) system: potential uses in drug and vaccine delivery. J Drug Target 1995; 2(6): 533-39.
31. Senior K. Bilosomes: the answer to oral vaccine delivery? Drug Discov Today 2001; 6(20): 1031-32.
32. Conacher M, Alexander J, Brewer JM. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine 2001; 19(20-22): 2965-74.
33. Shukla A, Singh B, Katare OP. Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano-bilosomes. Br J Pharmacol 2011; 164(2b): 820-7.
34. Shukla A, Katare OP, Singh B, et al. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes. Int J Pharm 2010; 385(1-2): 47-52.
35. Shukla A, Khatri K, Gupta PN, et al. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J Pharm Pharm Sci 2008; 11(1): 59-66.
36. Patel GB, Sprott GD. Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems. Crit Rev Biotechnol 1999; 19(4): 317-57.
37. Krishnan L, Dennis Sprott G. Archaeosomes as self-adjuvanting delivery systems for cancer vaccines. J Drug Target 2003; 11(8-10): 515-24.
38. Patel GB, Chen W. Archaeosome immunostimulatory vaccine delivery system. Curr Drug Deliv 2005; 2(4): 407-21.
39. Patel GB, Zhou H, KuoLee R, et al. Archaeosomes as adjuvants for combination vaccines. J Liposome Res 2004; 14(3-4): 191-202.
40. Patel GB, Zhou H, Ponce A, et al. Mucosal and systemic immune responses by intranasal immunization using archaeal lipidadjuvanted vaccines. Vaccine 2007; 25(51): 8622-36.
41. Kunisawa J, Nakagawa S, Mayumi T. Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development. Adv Drug Deliv Rev 2001; 52(3): 177-86.
42. Bonnet MC, Tartaglia J, Verdier F, et al. Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol Lett 2000; 74(1): 11-25.
43. Gaubert S, Delord B, Roux D, et al. Amplification of antibody responses to antigen using small multilamellar vesicles for delivery system. Drug Deliv 2005; 12(2): 69-74.
44. Moingeon P, de Taisne C, Almond J. Delivery technologies for human vaccine. British Med Bull 2002; 62: 29-44.
45. Bouter A, Delord B, Dransart E. Delivery technologies for human vaccine. Intracellular trafficking of Shiga-toxin-B-subunitfunctionalized spherulites. Biol Cell 2008; 100(12): 717-25.
46. Paul A, Cevc G, Bachhawat BK. Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. Vaccine 1998; 16(2-3): 188-95.
47. Vinod KR, Kumar MS, Anbazhagan S, et al. Critical issues related to transfersomes-novel vesicular system. Acta Sci Pol Technol Aliment 2012; 11(1): 67-82.
48. Gupta PN, Mishra V, Singh P, et al. Tetanus toxoid-loaded transfersomes for topical immunization. J Pharm Pharmacol 2005; 57(3): 295-01.
49. Rai K, Gupta Y, Jain A, et al. Transfersomes: self-optimizing carriers for bioactives. PDA J Pharm Sci Technol 2008; 62(5): 362-79.
50. Mahor S, Rawat A, Dubey PK, et al. Cationic transfersomes based topical genetic vaccine against hepatitis B. Int J Pharm 2007; 340(1-2): 13-9.
51. Samad A, Tariq M, Alam MI. Microsphere: A novel drug delivery system. In: Faunn M, editor. Colloids in drug delivery. Boca Raton: USA: CRC Press; 2010. p. 455-78.
52. Bramwell VW, Perrie Y. Particulate delivery systems for vaccines. Crit Rev Ther Drug Carrier Syst 2005; 22(2): 151-214.
53. De Temmerman ML, Rejman J, Demeester J, et al. Particulate vaccines: on the quest for optimal delivery and immune response. Drug 2011; 16(13-14): 569-82.
54. Esparza I, Kissel T. Parameters affecting the immunogenicity of microencapsulated tetanus toxoid. Vaccine 1992; 10(10): 714-20.
55. Kaji M, Kaji Y, Ohkuma K, et al. Phase 1 clinical tests of influenza MDP-virosome vaccine (KD-5382). Vaccine 1992; 10(10): 663-7.
56. Alonso MJ, Gupta RK, Min C, et al. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine 1994; 12(4): 299-306.
57. Kissel T, Koneberg R, Hilbert AK, et al. Microencapsulation of antigens using biodegradable polyesters: facts and phantasies. Behring Inst Mitt 1997; 9: 172-83.
58. Singh M, O'Hagan DT. Recent advances in vaccine adjuvants. Pharm Res 2002; 19(6): 715-28.
59. Raychaudhuri S, Rock KL. Fully mobilizing host defense: building better vaccines. Nat Biotechnol 1998; 16(11): 1025-31.
60. O'Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines 2003; 2(2): 269-83.
61. Kim KK, DW P. Microspheres for Drug Delivery. In: M. F, editor. BioMEMS and Biomedical Nanotechnology. USA: Springer; 2006. p. 19-50.
62. Hanes J, Chiba M, Langer R. Polymer microspheres for vaccine delivery. Pharm Biotechnol 1995; 6: 389-412.
63. Gupta RK, Chang AC, Siber GR. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems. Dev Biol Stand 1998; 92: 63-78.
64. Bramwell VW, Perrie Y. Particulate delivery systems for vaccines: what can we expect? J Pharm Pharmacol 2006; 58(6): 717-28.
65. Keegan ME, Saltzman WM. Surface-modified biodegradable microspheres for DNA vaccine delivery. Methods Mol Med 2006; 127: 107-13.
66. Eldridge JH, Staas JK, Meulbroek JA, et al. Biodegradable microspheres as a vaccine delivery system. Mol Immunol 1991; 28(3): 287-94.
67. Kirby DJ, Rosenkrands I, Agger EM, et al. PLGA microspheres for the delivery of a novel subunit TB vaccine. J Drug Target 2008; 16(4): 282-93.
68. Gupta RK, Chang AC, Griffin P, et al. Determination of protein loading in biodegradable polymer microspheres containing tetanus toxoid. Vaccine 1997; 15(6-7): 672-8.
69. Chang AC, Gupta RK. Stabilization of tetanus toxoid in poly(DLlactic-co-glycolic acid) microspheres for the controlled release of antigen. J Pharm Sci 1996; 85(2): 129-32.
70. Dos Santos SA, Zarate-Blades CR, de Sa Galetti FC, et al. A subunit vaccine based on biodegradable microspheres carrying rHsp65 protein and KLK protects BALB/c mice against tuberculosis infection. Hum Vaccin 2010; 6(12): 1047-53.
71. Bowey K, Neufeld RJ. Systemic and mucosal delivery of drugs within polymeric microparticles produced by spray drying. Bio-Drugs 2010; 24(6): 359-77.
72. Ahire VJ, Sawant KK, Doshi JB, et al. Chitosan microparticles as oral delivery system for tetanus toxoid. Drug Dev Ind Pharm 2007; 33(10): 1112-24.
73. Premaletha K, Licy CD, Jose S, et al. Formulation, characterization and optimization of Hepatitis B surface antigen (HBsAg)-loaded chitosan microspheres for oral delivery. Pharm Dev Technol 2012; 17(2): 251-8.
74. Uddin AN, Bejugam NK, Gayakwad SG, et al. Oral delivery of gastro-resistant microencapsulated typhoid vaccine. J Drug Target 2009; 17(7): 553-60.
75. Illum L, Jabbal-Gill I, Hinchcliffe M, et al. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001; 51(1-3): 81-96.
76. Kang ML, Cho CS, Yoo HS. Application of chitosan microspheres for nasal delivery of vaccines. Biotechnol Adv 2009; 27(6): 857-65.
77. Shaw A. New technologies for new influenza vaccines. Vaccine 2012; 30(33): 4927-33.
78. Sivakumar SM, Sukumaran N, Murugesan R, et al. Immune augmentation of single contact hepatitis b vaccine by using plga microspheres as an adjuvant. Indian J Pharm Sci 2008; 70(4): 487-90.
79. Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods 2006; 40(1): 60-5.
80. Wilschut J. Influenza vaccines: the virosome concept. Immunol Lett 2009; 122(2): 118-21.
81. Huckriede A, Bungener L, Stegmann T, et al. The virosome concept for influenza vaccines. Vaccine 2005; 23(Suppl 1): S26-38.
82. Gluck R, Moser C, Metcalfe IC. Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert Opin Biol Ther 2004; 4(7): 1139-45.
83. Mischler R, Metcalfe IC. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine 2002; 20(Suppl 5): B17-23.
84. Sarkar DP, Ramani K, Tyagi SK. In: Methods in Molecular Biology; Basu S, Basu M, Ed. New York: Humana Press 2002, Vol. 199: pp 163-173.
85. Yap I, Guan R, Chan SH. Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein--a preliminary study on immunogenicity. Vaccine 1992; 10(7): 439-42.
86. Moser C, Metcalfe IC, Viret JF. Virosomal adjuvanted antigen delivery systems. Expert Rev Vaccines 2003; 2(2): 189-96.
87. Gluck R, Burri KG, Metcalfe I. Adjuvant and antigen delivery properties of virosomes. Curr Drug Deliv 2005; 2(4): 395-400.
88. Bovier PA. Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev Vaccines 2008; 7(8): 1141-50.
89. Madalinski K, Sylvan SP, Hellstrom U, et al. Antibody responses to preS components after immunization of children with low doses of BioHepB. Vaccine 2001; 20(1-2): 92-7.
90. Shouval D, Ilan Y, Adler R, et al. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine 1994; 12(15): 1453-9.
91. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364(9447): 1757-65.
92. Nardin EH, Oliveira GA, Calvo-Calle JM, et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect Immun 2004; 72(11): 6519-27.
93. Lowell GH, Smith LF, Seid RC, et al. Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants. J Exp Med 1988; 167(2): 658-63.
94. Oliveira GA, Wetzel K, Calvo-Calle JM, et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun 2005; 73(6): 3587-97.
95. Frasch CE, Peppler MS. Protection against group B Neisseria meningitidis disease: preparation of soluble protein and proteinpolysaccharide immunogens. Infect Immun 1982; 37(1): 271-80.
96. Plante M, Jones T, Allard F, et al. Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge. Vaccine 2001; 20(1-2): 218-25.
97. Frenkel D, Puckett L, Petrovic S, et al. A nasal proteosome adjuvant activates microglia and prevents amyloid deposition. Ann Neurol 2008; 63(5): 591-601.
98. Burt D, Mallett C, Plante M, et al. Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations. Expert Rev Vaccines 2011; 10(3): 365-75.
99. Treanor J, Nolan C, O'Brien D, et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 2006; 24(3): 254-62.
100. Mallett CP, Hale TL, Kaminski RW, et al. Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection. Infect Immun 1995; 63(6): 2382-86.
101. Rao R, Squillante E, 3rd, Kim KH. Lipid-based cochleates: a promising formulation platform for oral and parenteral delivery of therapeutic agents. Crit Rev Ther Drug Carrier Syst 2007; 24(1): 41-61.
102. Mannino RJ, Canki M, Feketeova E, et al. Targeting immune response induction with cochleate and liposome-based vaccines. Adv Drug Deliv Rev 1998; 32(3): 273-87.
103. Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974; 252(5480): 252.
104. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol Today 1990; 11(3): 89-97.
105. Papahadjopoulos D, Vail WJ, Jacobson K, et al. Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim Biophys Acta 1975; 394(3): 483-91.
106. Lowell GH, MacDermott RP, Summers PL, et al. Antibodydependent cell-mediated antibacterial activity: K lymphocytes, monocytes, and granulocytes are effective against shigella. J Immunol 1980; 125(6): 2778-84.
107. Gould-Fogerite S, Edghill-Smith Y, Kheiri M, et al. Lipid matrixbased subunit vaccines: a structure-function approach to oral and parenteral immunization. AIDS Res Hum Retroviruses 1994; 10(Suppl 2): S99-103.
108. Gould-Fogerite S, Mannino RJ. Cochleates for induction of mucosal and systemic immune responses. In: Vaccine adjuvants: preparation methods and research protocols. O'Hagan DT, Ed. New York: USA: Human Press; 2000, Vol. 42, p. 179-96.
109. Haile M, Kallenius G. Recent developments in tuberculosis vaccines. Curr Opin Infect Dis 2005; 18(3): 211-5.
110. Zarif L, Mannino RJ. Cochleates. Lipid-based vehicles for gene delivery-concept, achievements and future development. Adv Exp Med Biol 2000; 465: 83-93.
111. Acevedo R, Callico A, del Campo J, et al. Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice. Methods 2009; 49(4): 309-15.
112. Perez O, Bracho G, Lastre M, et al. Proteliposome-derived Cochleate as an immunomodulator for nasal vaccine. Vaccine 2006; 24(Suppl 2): S2-52-3.
113. Campo JD, Zayas C, Romeu B, et al. Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses. Methods 2009; 49(4): 301-08.
114. Gould-Fogerite S, Kheiri M, Zhang F, et al. Cochleate Delivery Vehicles: Applications in vaccine delivery. J Liposome Res 2000; 10(4): 339-58.
115. Corporations with HIV Vaccine Programs. [Online] http://www.thebody.com/content/art31449.html (Accessed on 30th Jan, 2012).
116. O'Hagan D. In: Vaccine Adjuvants: Preparation methods and research protocols, Gould-Fogerite S, Mannino RJ. Ed. New York: Humana Press 2000, pp 179-189.
117. Gluck R, Mischler R, Brantschen S, et al. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest 1992; 90(6): 2491-95.
118. Moser C, Amacker M, Zurbriggen R. Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev Vaccines 2011; 10(4): 437-46.
119. Jackson DC, Crabb BS, Poumbourios P, et al. Three antibody molecules can bind simultaneously to each monomer of the tetramer of influenza virus neuraminidase and the trimer of influenza virus hemagglutinin. Arch Virol 1991; 116(1-4): 45-56.
120. Poltl-Frank F, Zurbriggen R, Helg A, et al. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. Clin Exp Immunol 1999; 117(3): 496-03.
121. Tamborrini M, Stoffel SA, Westerfeld N, et al. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations. Malar J 2011; 10: 359.
122. Calcagnile S, Zuccotti GV. The virosomal adjuvanted influenza vaccine. Expert Rev Vaccines 2010; 10(2): 191-200.
123. Daemen T, Bungener L, Huckriede A, et al. Virosomes as an antigen delivery system. J Liposome Res 2000; 10(4): 329-38.
124. Pedersen GK, Ebensen T, Gjeraker IH, et al. Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLoS One 2011; 6(11): e26973.
125. Stone WE, Mukherjee S, Smith M, Das SK. In: Methods in Molecular Biology; Basu S, Basu M, Ed. New York: Humana Press 2002; Vol. 199: pp 145-61.
126. Nordly P, Madsen HB, Nielsen HM, et al. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators. Expert Opin Drug Deliv 2009; 6(7): 657-72.
127. O'Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 2002; 15(5): 405-15.
128. Copland MJ, Rades T, Davies NM, et al. Lipid based particulate formulations for the delivery of antigen. Immunol Cell Biol 2005; 83(2): 97-105.
129. Barr IG, Mitchell GF. ISCOMs (immunostimulating complexes): the first decade. Immunol Cell Biol 1996; 74(1): 8-25.
130. Hu KF, Lovgren-Bengtsson K, Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev 2001; 51(1-3): 149-59.
131. Hu KF, Elvander M, Merza M, et al. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses. Clin Exp Immunol 1998; 113(2): 235-43.
132. Smith RE, Donachie AM, Mowat AM. Immune stimulating complexes as mucosal vaccines. Immunol Cell Biol 1998; 76(3): 263-69.
133. Foged C, Vader P, Schiffelers RM. Lipid-Based Formulations for siRNA Delivery. In: Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids and Vaccines; Jorgensen L, Nielsen HM, Ed. New Jersey, USA: Wiley Interscience; 2009.
134. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur J Pharm Biopharm 2000; 50(1): 161-77.
135. Samad A, Alam MI, Saxena K. Dendrimers: a class of polymers in the nanotechnology for the delivery of active pharmaceuticals. Curr Pharm Des 2009; 15(25): 2958-69.
136. Bernstein DI, Stanberry LR, Sacks S, et al. Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob Agents Chemother 2003; 47(12): 3784-88.
137. Heegaard PM, Boas U, Sorensen NS. Dendrimers for Vaccine and Immunostimulatory Uses. A Review. Bioconug Chem 2009 Nov 4. [Epub ahead of print].
138. Dufes C, Uchegbu IF, Schatzlein AG. Dendrimers in gene delivery. Adv Drug Deliv Rev 2005; 57(15): 2177-202.
139. Brown MD, Schatzlein AG, Uchegbu IF. Gene delivery with synthetic (non viral) carriers. Int J Pharm 2001; 229(1-2): 1-21.
140. Daftarian P, Kaifer AE, Li W, et al. Peptide-conjugated PAMAM dendrimer as a universal DNA vaccine platform to target antigenpresenting cells. Cancer Res 2011; 71(24): 7452-62.
141. Wright DC, Adjuvant properties of poly(amidoamine) dendrimers. US5795582, 1998.
142. Dutta T, Garg M, Jain NK. Poly(propyleneimine) dendrimer and dendrosome mediated genetic immunization against hepatitis B. Vaccine 2008; 26(27-28): 3389-94.
143. Cubillos C, de la Torre BG, Jakab A, et al. Enhanced mucosal immunoglobulin A response and solid protection against foot-andmouth disease virus challenge induced by a novel dendrimeric peptide. J Virol 2008; 82(14): 7223-30.
144. Kowalczyk W, de la Torre BG, Andreu D. Strategies and limitations in dendrimeric immunogen synthesis. The influenza virus M2e epitope as a case study. Bioconjug Chem 2010; 21(1): 102-10.
145. Niederhafner P, Reinis M, Sebestik J, et al. Glycopeptide dendrimers, part III: a review. Use of glycopeptide dendrimers in immunotherapy and diagnosis of cancer and viral diseases. J Pept Sci 2008; 14(5): 556-87.
146. Monso M, Tarradas J, de la Torre BG, et al. Peptide vaccine candidates against classical swine fever virus: T cell and neutralizing antibody responses of dendrimers displaying E2 and NS2-3 epitopes. J Pept Sci 2011; 17(1): 24-31.
147. Ribeiro S, Rijpkema SG, Durrani Z, et al. PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice. Int J Pharm 2007; 331(2): 228-32.
148. Beg S, Rizwan M, Sheikh AM, et al. Advancement in carbon nanotubes: basics, biomedical applications and toxicity. J Pharm Pharmacol 2011; 63(2): 141-63.
149. in het Panhuis M. Vaccine delivery by carbon nanotubes. Chem Biol 2003; 10(10): 897-98.
150. Salvador-Morales C, Flahaut E, Sim E, et al. Complement activation and protein adsorption by carbon nanotubes. Mol Immunol 2006; 43(3): 193-201.
151. Perry JL, Martin CR, Stewart JD. Drug-delivery strategies by using template-synthesized nanotubes. Chemistry 2011; 17(23): 6296-302.
152. Pastorin G, Kostarelos K, Prato M, et al. Functionalized Carbon Nanotubes: Towards the Delivery of Therapeutic Molecules. J Biomed Nanotechnol 2005; 1: 1-10.
153. Pantarotto D, Partidos CD, Hoebeke J, et al. Immunization with peptide-functionalized carbon nanotubes enhances virus-specific neutralizing antibody responses. Chem Biol 2003; 10(10): 961-6.
154. Chen W. Investigation of Functionalized carbon nanotubes as a delivery system for enhanced gene expression with implications in developing DNA vaccines for Hepatitis C Virus.: University of Saskatchewan; 2008.
155. Nunes A, Amsharov N, Guo C, et al. Hybrid polymer-grafted multiwalled carbon nanotubes for in vitro gene delivery. Small 2010; 6(20): 2281-91.
156. Cheung W, Pontoriero F, Taratula O, et al. DNA and carbon nanotubes as medicine. Adv Drug Deliv Rev 2010; 62(6): 633-49.
157. Li S, He P, Dong J, et al. DNA-directed self-assembling of carbon nanotubes. J Am Chem Soc 2005; 127(1): 14-5.